Literature DB >> 22210269

Targeting interleukin-33 in rheumatoid arthritis.

Chao Rong, Wei Hu, Fan-Rong Wu, Fei-Hu Chen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22210269     DOI： 10.1007/s00296-011-2299-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  7 in total

1.  IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy.

Authors:  Waldiceu A Verri; Fabrício O Souto; Silvio M Vieira; Sergio C L Almeida; Sandra Y Fukada; Damo Xu; Jose C Alves-Filho; Thiago M Cunha; Ana T G Guerrero; Rafaela B Mattos-Guimaraes; Fabíola R Oliveira; Mauro M Teixeira; João S Silva; Iain B McInnes; Sergio H Ferreira; Paulo Louzada-Junior; Foo Y Liew; Fernando Q Cunha
Journal:  Ann Rheum Dis       Date:  2010-05-14       Impact factor: 19.103

Review 2.  IL-33: a promising therapeutic target for rheumatoid arthritis?

Authors:  Feng-Lai Yuan; Xia Li; Wei-Guo Lu; Cheng-Wan Li; Rui-Sheng Xu; Jian Dong
Journal:  Expert Opin Ther Targets       Date:  2011-02-26       Impact factor: 6.902

3.  Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis.

Authors:  Rong Mu; He-Qing Huang; Yu-Hui Li; Chun Li; Hua Ye; Zhan-Guo Li
Journal:  J Rheumatol       Date:  2010-08-03       Impact factor: 4.666

4.  Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1β signaling and a poor clinical response.

Authors:  Yasushi Matsuyama; Hitoaki Okazaki; Motoaki Hoshino; Sachiko Onishi; Yasuyuki Kamata; Katsuya Nagatani; Takao Nagashima; Masahiro Iwamoto; Taku Yoshio; Hiromi Ohto-Ozaki; Hiroyuki Tamemoto; Mayumi Komine; Hitoshi Sekiya; Shin-Ichi Tominaga; Seiji Minota
Journal:  Rheumatol Int       Date:  2011-03-24       Impact factor: 2.631

5.  IL-33 exacerbates autoantibody-induced arthritis.

Authors:  Damo Xu; Hui-Rong Jiang; Yubin Li; Peter N Pushparaj; Mariola Kurowska-Stolarska; Bernard P Leung; Rong Mu; Hwee Kee Tay; Andrew N J McKenzie; Iain B McInnes; Alirio J Melendez; Foo Y Liew
Journal:  J Immunol       Date:  2010-02-05       Impact factor: 5.422

6.  Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis.

Authors:  Gaby Palmer; Dominique Talabot-Ayer; Céline Lamacchia; Dean Toy; Christian A Seemayer; Sébastien Viatte; Axel Finckh; Dirk E Smith; Cem Gabay
Journal:  Arthritis Rheum       Date:  2009-03

7.  IL-33 exacerbates antigen-induced arthritis by activating mast cells.

Authors:  Damo Xu; Hui-Rong Jiang; Peter Kewin; Yubin Li; Rong Mu; Alasdair R Fraser; Nick Pitman; Mariola Kurowska-Stolarska; Andrew N J McKenzie; Iain B McInnes; Foo Y Liew
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-30       Impact factor: 11.205
  7 in total
  1 in total

1.  Geometrical Frustration in Interleukin-33 Decouples the Dynamics of the Functional Element from the Folding Transition State Ensemble.

Authors:  Kaitlin M Fisher; Ellinor Haglund; Jeffrey K Noel; Kendra L Hailey; José N Onuchic; Patricia A Jennings
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.